Filing Summary
Company: NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI). Filing: Form 8-K dated September 28, 2026.
Business context and reporting period
This is a current report, not a periodic financial report. The company announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on November 17, 2026, for an in-person End-of-Phase 1 Type B meeting concerning NEO212.
Financial and operating metrics
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial results.
Material changes and outlook
The disclosed development is the scheduled FDA meeting. The filing does not state the meeting’s expected outcome, provide clinical data, or give financial guidance or an updated business outlook. The referenced September 28 press release is identified as Exhibit 99.1, but its text is not included in the supplied filing content.
Key facts to verify
- Whether the FDA meeting took place as scheduled and any resulting feedback on NEO212.
- The clinical data and development plans discussed in the press release or later company disclosures.
- Any subsequent filings or announcements providing financial information or changes to the development timeline.